Lex Favios starts healthcare practice

0
1869
LinkedIn
Facebook
Twitter
Whatsapp
Telegram
Copy link

Lex Favios has launched a pharmaceutical, medical devices, diagnostics and healthcare practice, headed by Rakesh Sharma and Kavitha Sripada. Sharma and Sripada both joined the firm on 1 April and have previously worked at Becton Dickinson India, a medical technology company.

Sharma worked at Becton Dickinson India for over 20 years, most recently as the head of regulatory affairs, government relations, public policy, and materials. He has been associated with the Ministry of Health, the office of the Drugs Controller General of India, the Consumer Affairs Ministry, the Finance Ministry, the Bureau of Indian Standards, and the Ministry of Science and Technology.

Lex Favios starts healthcare practiceHe has also been part of various committees formed by these ministries and assisted with the formulation of policies and regulations. He has helped draft rules under the current Drugs and Cosmetics Act for devices, assisted with the drafting of a separate act for medical devices, and drafted rules for the price control of devices by the National Pharmaceutical Pricing Authority under the Make in India initiative.

[ihc-hide-content ihc_mb_type=”show” ihc_mb_who=”3″ ihc_mb_template=”2″ ]

Sripada has over 20 years of experience as an in-house counsel, at Becton Dickinson India, SmithKline Beecham and other such companies. She has advised on litigation in the areas of healthcare and life sciences, intellectual property, and advertising law.

Sripada has also advised clients on the regulatory side of healthcare, representing hospitals, health professionals, health agencies, medical device manufacturers, suppliers, investment funds, and healthcare management companies in a variety of transactional, regulatory and operational matters.

The new practice will be staffed by a team with extensive experience in advising on intellectual property infringement of pharmaceutical products, medical devices, dietary supplements, proprietary medicines, the Drugs and Cosmetics Act, and requirements and transactions involving the development, manufacture and commercialization of medicinal products.

[/ihc-hide-content]

LinkedIn
Facebook
Twitter
Whatsapp
Telegram
Copy link